Blood test could replace needle biopsies for bile duct cancer patients
NCT ID NCT07151118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive to identify which patients might benefit from targeted therapies. Researchers will enroll 100 adults in Korea who have advanced biliary tract cancer and compare the blood test results with standard tissue testing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHA Bundang Medical Center
RECRUITINGSeongnam-si, Gyeonggi-do, 13496, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?